Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

• a pharmaceutical composition comprising the compound or
• a method of inhibiting production of amyloid-b protein and/or of treating or preventing a neurodegenerative disease, such as Alzheimer- type dementia and Down's syndrome the method involving administering to a human subject suffering from the condition a therapeutically or prophylactically effective amount of a compound or pharmaceutically acceptable salt thereof according to any one of [1] to [10] above or the pharmaceutical composition according to [11] above; and
• the fused aminodihydropyrimidone derivative of the formula (I) according to the present invention is preferably a compound of the formula (I), wherein Y is -NR Y - (wherein R ⁇ is a hydrogen atom, a C 1-6 alkyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ , a C 1-6 alkylcarbonyl group which 5 optionally has 1 to 3 substituents selected from Substituent Group ⁇ , a C 6-14
• arylcarbonyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ , a C 1-6 alkylsulfonyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ , a C 6-14 arylsulfonyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ , a C 6-14 aryl group which optionally has0 1 to 3 substituents selected from Substituent Group ⁇ or a 5- to 10-membered
• Ring A, Ring B, R 3 , R 4 , R 5 and R 6 are as hereinbefore defined and R x is methyl or ethyl.
• R x is methyl or ethyl.
• the "leaving group" in the raw material compound used in preparation of the compound (I) according to the present invention may be any leaving group used for nucleophilic substitution reaction.
• the leaving group include a halogen atom, a alkylsulfonyloxy group which may be substituted with the above Substituent Group ⁇ and an arylsulfonyloxy group which may be substituted with the above Substituent Group ⁇ .
• Specific examples of the leaving group include a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group, a
• the condensation reaction of the compound (3-3) with the compound (3-4) using a condensing agent can be performed under the same conditions as those usually used and described in the following documents.
• Examples of the known method include those in Rosowsky, A.; Forsch, R. A.; Moran, R. G.; Freisheim, J. H.; J. Med. Chem., 34 (1), 227-234 (1991), Brzostwska, M.; Brossi, A.; Flippen-Anderson, J. L.;
• the reaction using zinc such as zinc-acetic acid can be performed under the same conditions as those described in J. Org. Chem. 2003, 68, 1207-1215 and Org. Lett. 7 (2005) 25, 5741-5742, for example.
• the acid used include acetic acid, formic acid and hydrochloric acid.
• the solvent used in the reaction is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Examples of the solvent include methanol, ethanol, 1,4-dioxane, THF and water.
• the above acid may also be used as a solvent.
• the reaction temperature is usually -20°C to solvent reflux temperature, and preferably ice-cold temperature to solvent reflux temperature.
• the reaction time is not particularly limited and is usually 5 minutes to 48 hours, and preferably 5 minutes to 24 hours.
• This step is a method of obtaining compound (5-10) by condensing the compound (5-8) with compound (5-9) and then cyclizing the resultant compound.
• the condensation and cyclisation can be performed by treating with a coupling reagent such as EDCI.
• a coupling reagent such as EDCI.
• the solvent used in the reaction is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Examples of the solvent include DMF, dichloromethane, acetonitrile, and THF.
• This step is a step of obtaining the compound (6-4) by deprotecting the acetal group of the compound (6-6).
• This step is a step of obtaining the compound (6-3) by deprotecting the hydroxyl protecting group of the compound (6-8).
• the hydroxyl protecting group used in this step is not particularly limited.
• the organometallic catalyst used in this reaction is not particularly limited.
• the organometallic catalyst include metal catalysts such as tetrakis(triphenylphosphine)palladium (0), dichlorobis(triphenylphosphine)palladium (II), [l,l'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride, bis(tert- butylphosphine)palladium (0), palladium (II) acetate and [1,3- bis(diphenylphosphino)propane]nickel (II), and mixtures of these metal catalysts.
• metal catalysts such as tetrakis(triphenylphosphine)palladium (0), dichlorobis(triphenylphosphine)palladium (II), [l,l'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride, bis(
• alkylsulfonyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇
• a C ⁇ -u arylsulfonyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇
• a 3- to 10-membered carbocyclic group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ or a 5- to 10-membered
• This step is a step of synthesizing a compound (11-2) from the compound (11-1) as a raw material using a method described in the above preparation method (Step 9-1).
• R 1 and R 2 are a Q. 6 alkyl group which may have 1 to 3 substituents selected from Substituent Group ⁇ , a C 1-6 alkylcarbonyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ , a C ⁇ -u arylcarbonyl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ , a Q. 6
• a more preferable result such as an improved yield may be achieved by carrying out this reaction in an oxygen atmosphere.
• Ring A, Ring B, R 3 , R 4 , R 5 , R 6 , R x , L, Z, Prt 3 and LV are as defined above;
• Ring D represents a C 6-14 aryl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ or a 5- to 6-membered heteroaryl group which optionally has 1 to 3 substituents selected from Substituent Group ⁇ ;
• R 10 represents a C 6-14 aryl group which optionally has 1 to 3 substituents selected from
• trifluoromethanesulfonate derivative or the heteroaryloxy trifluoromethanesulfonate derivative used in this step can be a commercially available product used as is, and can also be prepared from a commercially available product by a method known to a person skilled in the art.
• the nucleophilic aromatic substitution (SNAr reaction) used in this step can be performed under the same conditions as those generally used (such as the conditions according to methods described in documents such as Org. Prep. Proced. int. 39 (2007) 4, 399-402, Bioorg. Med. Chem. Lett. 15 (2005) 9, 2409-2413 and Bioorg. Med. Chem. Lett. 15 (2005) 3, 719-723).
• the dose of the fused aminodihydropyrimidone derivative or pharmaceutically acceptable salt thereof or solvate thereof according to the present invention varies according to the degree of symptoms, age, sex, body weight, mode of administration, type of salt and specific type of disease, for example.
• the active ingredient is orally administered to an adult at about 30 ⁇ g to 10 g, preferably 100 ⁇ g to 5 g, and more preferably 100 ⁇ g to 1 g per day, or is administered to an adult by injection at about 30 ⁇ g to 1 g, preferably 100 ⁇ g to 500 mg, and more preferably 100 ⁇ g to 300 mg per day, in one or several doses, respectively.
• Step 9 ( ⁇ H4aS ⁇ 7aS*)-2-Amino-7a-(2-fluoro-5-nitrophenyl)-3-methyl-4a,5,7,7a- tetrahvdrofuror3,4-dlpyrimidin-4(3H)-one
• Step 10 ( ⁇ )-tert-Butyl ((4aS*,7aS*)-7a-(2-fluoro-5-nitrophenyl)-3-methyl-4-oxo-
• tert-Butyl (methylcarbamothioyl)carbamate (2.13 g, 11.2 mmol) was added to a stirred mixture of (2R,3S,4S)-methyl 4-amino-4-(2-fluorophenyl)-2-methyltetrahydrofuran-3- carboxylate (2.27 g, 9.0 mmol), N-ethyl-N-(propan-2-yl)propan-2-amine (3.9 mL, 22.4 mmol) and N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride (1:1) (2.15 g, 11.2 mmol) in dry DMF (18 mL) at RT under nitrogen. The mixture was stirred at RT for 3 days, then partitioned between EtOAc (50 mL) and saturated aqueous
• N,N-dimethylpyridin-4-amine ( ⁇ 2 mg) was added to a stirred solution of the
• Trifluoroacetic acid (1 niL) was added to a stirred solution of tert-butyl ((4aS,5S,7aS)- 7a-(5-(5-(difluoromethyl)pyrazine-2-carboxamido)-2-fluorophenyl)-3-methyl-4-oxo-5- (trifluoromethyl)-3,4,4a,5,7,7a-hexahydrofuro[3,4-d]pyrimidin-2-yl)carbamate (92 mg, 0.15 mmol) in DCM (2 rnL) at RT. After 1 h at this temperature the volatiles were removed in vacuo and the residue was azeotroped with PhMe (x2).
• Example 11 N-(3-((4aS,5S,7aS)-2-Amino-3-methyl-4-oxo-5-(trifluoromethyl)- 3,4,4a,5J,7a-hexahvdrofuror3,4-dlpyrimidin-7a-yl)-4-fluorophenyl)-5- cyanopicolinamide
• Step 7 N-(3-((4aS,5S,7aS)-2-Amino-3-ethyl-4-oxo-5-(trifluoromethyl)-3,4,4a,5,7,7a- hexahydrofuror3,4-dlpyrimidin-7a-yl)-4-fluorophenyl)-5-(difluoromethyl)pyrazine-2- carboxamide
• DNase (Sigma D5025, St. Louis, MO, USA) at 37°C for 30 minutes to disperse the cells.
• the enzymatic reaction was stopped by adding inactivated horse serum to the solution.
• the enzymatically treated solution was centrifuged at 1,500 rpm for five minutes to remove the supernatant. 5 to 10 mL of a medium was added to the resulting cell mass.
• Neurobasal medium Invitrogen Corp. Cat #21103-049, Carlsbad, CA, USA
• B27 supplement Invitrogen Corp.
• the MTT lysis buffer was prepared as follows. 100 g of SDS (sodium dodecyl sulfate, sodium lauryl sulfate), WAKO 191-07145, Osaka, Japan) was dissolved in a mixed solution of 250 mL of N,N-dimethylformamide (WAKO 045-02916, Osaka, Japan) with
• A550_sample absorbance at 550 nm of sample well
• A550_bkg absorbance at 550 nm of background well
• A550_CTRL absorbance at 550 nm of control group well

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=41058390

Family Applications (1)

Country Status (10)

Cited By (29)

Families Citing this family (6)

Citations (9)

Family Cites Families (32)

• 2009
  • 2009-07-22 GB GB0912777A patent/GB0912777D0/en not_active Ceased
• 2010
  • 2010-07-21 KR KR20127004626A patent/KR20120052343A/ko not_active Ceased
  • 2010-07-21 CA CA2768881A patent/CA2768881A1/en not_active Abandoned
  • 2010-07-21 US US13/386,199 patent/US9139594B2/en not_active Expired - Fee Related
  • 2010-07-21 CN CN201080034140.0A patent/CN102574864B/zh not_active Expired - Fee Related
  • 2010-07-21 JP JP2012521034A patent/JP5699146B2/ja not_active Expired - Fee Related
  • 2010-07-21 EP EP20100734143 patent/EP2456771A1/en not_active Withdrawn
  • 2010-07-21 AU AU2010275196A patent/AU2010275196B2/en not_active Ceased
  • 2010-07-21 IN IN688DEN2012 patent/IN2012DN00688A/en unknown
  • 2010-07-21 WO PCT/EP2010/060586 patent/WO2011009897A1/en not_active Ceased

Patent Citations (9)

Non-Patent Citations (40)

Also Published As

Similar Documents

Legal Events